Medical Training AIAdvanced Lipid Management
You'll be able to select and sequence advanced lipid-lowering therapy, including PCSK9 inhibitors and other non-statin agents, for patients who don't reach LDL goals on statins alone.
What this track covers
This track covers lipid management beyond first-line statin therapy: risk stratification with ASCVD scoring and coronary artery calcium, optimizing statin intensity and managing intolerance, and adding non-statin agents such as PCSK9 inhibitors, bempedoic acid, ezetimibe, and inclisiran. It also addresses special cases like familial hypercholesterolemia, elevated Lp(a), and hypertriglyceridemia.
What you will practice
- Calculating ASCVD risk and applying risk enhancers to set LDL targets
- Choosing high-intensity statin regimens and troubleshooting statin intolerance
- Identifying candidates for PCSK9 inhibitor therapy and navigating prior authorization
- Sequencing non-statin add-on therapies when LDL goals aren't met
- Recognizing and managing familial hypercholesterolemia and severe hypertriglyceridemia
Simulator scenario
A patient on high-intensity statin therapy with persistently elevated LDL returns for follow-up, requiring the clinician to reassess risk, address possible statin intolerance, and decide on next-step therapy.
Board question topics
- ASCVD risk calculation and risk enhancers
- Statin intensity selection and intolerance management
- PCSK9 inhibitor and non-statin therapy indications
- Familial hypercholesterolemia and Lp(a) management
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free